ABL1 and Neurodevelopmental delay: Src, Abl, and Fyn, have also been associated with NDD pathology, including microglial activation, tau phosphorylation, and neurodegeneration, and have been investigated as therapeutic targets (Hebron et al., 2013b; Fowler et al., 2019).